# A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-120 and AD-120A

> **NCT06916130** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Addpharma Inc.** · enrollment: 48 (estimated)

## Conditions studied

- Gastroesophageal Reflux Disease (GERD)

## Interventions

- **DRUG:** AD-120A
- **DRUG:** AD-120

## Key facts

- **NCT ID:** NCT06916130
- **Lead sponsor:** Addpharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-04-21
- **Primary completion:** 2025-09-01
- **Final completion:** 2025-09-01
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06916130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06916130, "A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-120 and AD-120A". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT06916130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*